1. Home
  2. CPBI vs ACRV Comparison

CPBI vs ACRV Comparison

Compare CPBI & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Central Plains Bancshares Inc.

CPBI

Central Plains Bancshares Inc.

HOLD

Current Price

$18.38

Market Cap

73.5M

Sector

N/A

ML Signal

HOLD

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$1.62

Market Cap

82.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CPBI
ACRV
Founded
2023
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
73.5M
82.2M
IPO Year
2023
2022

Fundamental Metrics

Financial Performance
Metric
CPBI
ACRV
Price
$18.38
$1.62
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$11.67
AVG Volume (30 Days)
4.9K
478.4K
Earning Date
06-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
15.13
EPS
0.80
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$568.17
P/E Ratio
$22.98
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.52
$1.08
52 Week High
$18.75
$3.56

Technical Indicators

Market Signals
Indicator
CPBI
ACRV
Relative Strength Index (RSI) 63.80 40.40
Support Level $16.88 $1.51
Resistance Level N/A $1.86
Average True Range (ATR) 0.17 0.12
MACD 0.09 -0.03
Stochastic Oscillator 74.29 7.61

Price Performance

Historical Comparison
CPBI
ACRV

About CPBI Central Plains Bancshares Inc.

Central Plains Bancshares Inc operates as the bank holding company for Home Federal Savings and Loan Association of Grand Island that provides mortgage, consumer, commercial real estate, and commercial loans, The bank business consists mainly of accepting deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential mortgage loans secured by properties located in primary market area, as well as commercial real estate loans.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

Share on Social Networks: